Protara Therapeutics, Inc. (NASDAQ:TARA – Get Rating) – Equities researchers at Oppenheimer raised their Q2 2022 earnings per share estimates for Protara Therapeutics in a report released on Wednesday, May 11th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings per share of ($1.25) for the quarter, up from their prior estimate of ($1.38). Oppenheimer also issued estimates for Protara Therapeutics’ Q3 2022 earnings at ($1.50) EPS, Q4 2022 earnings at ($1.76) EPS, FY2022 earnings at ($5.44) EPS, FY2023 earnings at ($2.98) EPS, FY2024 earnings at ($1.75) EPS and FY2025 earnings at $0.07 EPS.
Protara Therapeutics (NASDAQ:TARA – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.19).
TARA opened at $2.89 on Monday. Protara Therapeutics has a fifty-two week low of $2.72 and a fifty-two week high of $11.10. The company has a market cap of $32.52 million, a price-to-earnings ratio of -0.73 and a beta of 1.10. The firm has a 50 day simple moving average of $4.42 and a 200 day simple moving average of $5.55.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Protara Therapeutics by 9.7% during the third quarter. BlackRock Inc. now owns 44,036 shares of the company’s stock worth $306,000 after purchasing an additional 3,911 shares during the last quarter. Bank of America Corp DE boosted its holdings in Protara Therapeutics by 1,217.6% during the fourth quarter. Bank of America Corp DE now owns 6,878 shares of the company’s stock worth $47,000 after purchasing an additional 6,356 shares during the last quarter. State Street Corp boosted its holdings in Protara Therapeutics by 30.7% during the fourth quarter. State Street Corp now owns 29,800 shares of the company’s stock worth $201,000 after purchasing an additional 7,000 shares during the last quarter. Trexquant Investment LP acquired a new position in Protara Therapeutics during the third quarter worth $86,000. Finally, Jump Financial LLC acquired a new position in Protara Therapeutics during the third quarter worth $100,000. Institutional investors and hedge funds own 61.25% of the company’s stock.
In related news, Director Luke M. Beshar purchased 10,000 shares of Protara Therapeutics stock in a transaction dated Monday, March 14th. The stock was bought at an average price of $4.25 per share, for a total transaction of $42,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 22,345 shares of company stock valued at $98,215 in the last quarter. Corporate insiders own 11.30% of the company’s stock.
Protara Therapeutics Company Profile (Get Rating)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
- Get a free copy of the StockNews.com research report on Protara Therapeutics (TARA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Protara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.